3rd Quarter - Report

NATIONAL PSORIASIS FOUNDATION for NATIONAL PSORIASIS FOUNDATION

Firm
Client
Income
—
Expenses
$53,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Support for the continuation of psoriasis and psoriatic arthritis data collection efforts at the Centers for Disease Control and Prevention (CDC). Allocate $1.2 million in the Fiscal Year 2013 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at CDC. With this funding, the CDCs National Center for Chronic Disease Prevention and Health Promotion could begin implementation of its public health agenda that, if implemented, will: 1. Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race and ethnicity affect the course and burden of psoriasis; 2. Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; 3. Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and 4. Gain insight into the long-term impact of psoriasis and psoriatic arthritis.

LobbyistCovered position, as disclosed
NIVA HAYNES —
SARA KOFMAN —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE; Natl Institutes of Health (NIH)

Health Issues HCR

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

LobbyistCovered position, as disclosed
NIVA HAYNES —
SARA KOFMAN —

Contacted: Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2033 (112th), H.R. 4209 (112th), S. 1107 (112th)

Medical/Disease Research/Clinical Labs MED

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

LobbyistCovered position, as disclosed
NIVA HAYNES —
SARA KOFMAN —

Contacted: SENATE; Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2033 (112th), S. 1107 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.